Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 studyResearch in context

Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 studyResearch in context

Summary: Background: Despite progress in the treatment of Waldenström macroglobulinaemia, this disease still remains a therapeutic challenge, especially in older patients with multiple comorbidities. This study aimed to assess obinutuzumab single-agent induction and maintenance activity and safety...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomasz Wróbel, Elżbieta Kalicińska, Jan Maciej Zaucha, Marta Morawska, Krzysztof Giannopoulos, Krzysztof Jamroziak, Ewa Lech-Marańda, Michał Taszner, Agnieszka Szeremet, Bartosz Małecki, Agnieszka Druzd-Sitek, Anna Łojko-Dankowska, Dominik Dytfeld
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:EClinicalMedicine
Subjects:
Waldenström macroglobulinaemia
Obinutuzumab monotherapy
Immunotherapy
CD20 antibody
Lymphoplasmacytic lymphoma
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537025003153
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589537025003153

Similar Items